| Name | AC710 |
| Description | AC710 is a potent PDGFR inhibitor with Kds of 0.6 nM for FLT3, 1 nM for KIT, 1.57 nM for CSF1R, 1.3 nM for PDGFRα, and 1 nM for PDGFRβ. |
| Animal Research | The antitumor efficacy of AC710 is assessed in a subcutaneous flank-tumor xenograft model in athymic nude mice using the MV4-11cell line. AC710 is dosed at 0.3, 3, and 30 mg/kg for 2 weeks. Tumor growth and body weight are monitored. |
| In vivo | At a dosage of 0.3 mg/kg, AC710 transiently inhibits tumor growth, with rapid resumption following cessation. Doses of 3 and 30 mg/kg result in complete tumor regression and prolonged suppression of tumor volume post-treatment. Notably, administration of AC710 does not lead to bodyweight loss in treated animals across all tested doses. Further, AC710 significantly mitigates disease progression in a mouse collagen-induced arthritis (CIA) model in a dose-dependent manner, starting from a low dose of 3 mg/kg over a span of 15 days (day 0-14). At increased dosages of 10 and 30 mg/kg, AC710's effectiveness in reducing joint swelling and inflammation is comparable or slightly superior to that of dexomethasone administered at a safe dose. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 15 mg/mL (26.66 mM), Sonication and heating are recommended.
|
| Keywords | Fms like tyrosine kinase 3 | Cluster of differentiation antigen 135 | CD117 | Platelet-derived growth factor receptor | PDGFR | CD135 | Inhibitor | AC 710 | AC-710 | c-Kit | AC710 | FLT3 | SCFR | inhibit |
| Inhibitors Related | Gilteritinib | Nintedanib | Regorafenib monohydrate | Sorafenib | Pexidartinib | Dasatinib | Regorafenib | Sorafenib tosylate | Lenvatinib mesylate | Imatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Compound Library |
United States
